Suptavumab
Based on 1 Customer Validation
Suptavumab (REGN2222) is a human monoclonal antibody. Suptavumab can bind and block a conserved epitope on RSV A and B subtypes. Suptavumab can be used for the research of RSV infection.
For research use only. We do not sell to patients.
- Purity : ≥95.0%
- CAS No.: 1629615-23-1
- Molecular Weight:145.8 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-P99804
ClesrovimabAnti-RSV Monoclonal Antibody -
HY-P9944
PalivizumabRSV Inhibitor -
HY-P99756
NirsevimabAnti-RSV Antibody -
HY-P99209
MotavizumabAnti-RSV mAb -
HY-109142
ZiresovirRSV F Inhibitor -
HY-16727
PresatovirRSV Fusion Inhibitor -
HY-12983
ALS-8112 -
HY-12993
RSV604RSV Replication Inhibitor -
HY-12983A
LumicitabineRSV Polymerase Inhibitor -
HY-123475
SisunatovirRSV-F Protein Inhibitor -
HY-120632
BMS-433771RSV Inhibitor -
HY-102038
PC786RSV Inhibitor
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Virus
IC50 & Target
RSV-F
In Vitro
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Accession
A0A0X8XRK2
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 1629615-23-1
-
Appearance Liquid
-
Molecular Weight 145.8 kDa
-
Color Colorless to light yellow
-
SMILES
[Suptavumab]
-
Synonyms
REGN2222
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
-
Data Sheet (256 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Simões EAF, et al. Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants. Clin Infect Dis. 2021 Dec 6;73(11):e4400-e4408. [Content Brief]
[2]. Rodriguez-Fernandez R, et al. Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Infection. Pediatr Infect Dis J. 2021 May 1;40(5S):S35-S39. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Suptavumab Related Classifications
HY-P99586 Related Classifications
Powered by Bioz